Organization (Academic)
Kumamoto University
ClinicalTrials.gov lists Kumamoto University as lead sponsor of 23 trials. It has 15 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo 熊本大学, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Kumamoto University: 23 lead-sponsored trials and 1 legal-entity registration.
Disease areas (41)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Disease | 11 |
| Coronary Artery Disease | 9 |
| Hypertension | 3 |
| Renal Insufficiency, Chronic | 3 |
| Atherosclerosis | 2 |
Showing 5 of 41 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 2 |
| 2013 | 1 |
| 2012 | 1 |
| 2010 | 3 |
| 2009 | 1 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: none of the 23 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (15)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe] | 1 |
| ARB | 1 |
| No aspirin | 1 |
| Lipid Lowering Treatment | 1 |
| Lipitor (Atorvastatin) monotherapy | 1 |
Showing 5 of 15 approved assets.
Journals published in (48)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Acta oto-laryngologica | 4 |
| Diabetes care | 3 |
| Journal of the American Heart Association | 3 |
| Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | 3 |
| The Laryngoscope | 3 |
Showing 5 of 48 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 14 | 0 | 2015-11-17 |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Hiroshima University | Co sponsors trial with | 1 |
| Hokkaido University Hospital | Co sponsors trial with | 1 |
| Fogarty International Center of the National Institute of Health | Co sponsors trial with | 1 |
Latest dated events (41)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-03-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2018-10-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2017-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 41 events.
Biomarker capability evidence (9)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| MVD | Trial collaborator | Named in trial inclusion criteria |
| SLC25A13 | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| COL3A1 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar) |
| CYP2C19 | Trial sponsor | Biospecimen collected in a trial |
Showing 5 of 9 evidence rows.
Biomarkers this organization publishes on (272)
Shown in this order: most publications first.
Showing 5 of 272 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.